News
Fortrea sells pair of businesses to private equity firm to become 'pure-play' CRO AI is already widely used in drug development and is advancing into clinical trials, too, as evidenced by the many ...
However, the nuts and bolts of clinical trials are rooted in quite traditional methods and processes. Fortrea aims to modernize the way clinical trials are run with innovation that combines the ...
Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies. Fortrea has extensive experience ...
Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies. Fortrea has extensive experience ...
The growth is driven by pharma and biotech companies outsourcing clinical trials to specialized providers. Since late-stage trials are larger and more complex, they are more frequently outsourced ...
Fortrea, a recent Labcorp spin-off ... According to this March 2024 article by PharmaExec.com, new clinical trials were down 15% in 2023 from 2022 and down 21% in 2023 from 2021 The article ...
Clinical research company Fortrea Holdings (NASDAQ:FTRE) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $651.3 million. The company’s full-year revenue ...
Hosted on MSN3mon
Fortrea (NASDAQ:FTRE) Misses Q4 Revenue Estimates, Stock DropsSpun off from Labcorp in 2023, Fortrea Holdings (NASDAQ:FTRE) provides contract research and development services for pharmaceutical and biotechnology companies, specializing in clinical trials ...
However, the nuts and bolts of clinical trials are rooted in quite traditional methods and processes. Fortrea aims to modernize the way clinical trials are run with innovation that combines the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results